Barely Significant
← all excerpts

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Haematologica · 2019 · PMC6312036 · PMID 30171024

Europe PMCDOI
1
hedged sentence
0.0470
closest p · 0.9× alpha
0.0470
boldest claim

The sentences

weakly significantP =0.047actually significant
Molecular blood MRD status at mid-term was also significant for PFS ( P =0.01) and weakly significant for OS ( P =0.047) ( Table 2 ).

also in 1,387 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.